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Abstract
Introduction: Community acquired pneumonia (CAP) is a major cause of morbidity and mortality. While there is
much data about risk factors for severe outcome in the general population, there is less focus on younger group
of patients. Therefore, we aimed to detect simple prognostic factors for severe morbidity and mortality in young
patients with CAP.
Methods: Patients of 60 years old or younger, who were diagnosed with CAP (defined as pneumonia identified 48
hours or less from hospitalization) between March 1, 2005 and December 31, 2008 were retrospectively analyzed
for risk factors for complicated hospitalization and 90-day mortality.
Results: The cohort included 637 patients. 90-day mortality rate was 6.6% and the median length of stay was 5
days. In univariate analysis, male patients and those with co-morbid conditions tended to have complicated
disease. In multivariate analysis, variables associated with complicated hospitalization included post chest radiation
state, prior neurologic damage, blood urea nitrogen (BUN) > 10.7 mmol/L and red cell distribution width (RDW) >
14.5%; whereas, variables associated with an increased risk of 90-day mortality included age ≥ 51 years, prior
neurologic damage, immunosuppression, and the combination of abnormal white blood cells (WBC) and elevated
RDW. Complicated hospitalization and mortality rate were significantly higher among patients with increased RDW
regardless of the white blood cell count. Elevated RDW was associated with a significant increase in complicated
hospitalization and 90-day mortality rates irrespective to hemoglobin levels.
Conclusions: In young patients with CAP, elevated RDW levels are associated with significantly higher rates of
mortality and severe morbidity. RDW as a prognostic marker was unrelated with hemoglobin levels.
Trial registration: ClinicalTrials.Gov NCT00845312
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Introduction
Community acquired pneumonia (CAP) is a major cause
of severe morbidity and mortality. It is the sixth most
common cause of death in the USA, and it is estimated
that four million cases of CAP occur annually [1]. There
is a worldwide increase in the number of hospitaliza-
tions due to CAP in the general population [2-4].
Much research has been conducted in recent decades
to determine prognostic factors for adverse outcome in
patients hospitalized for CAP, including concomitant
diseases and laboratory parameters on admission [5].
Several prognostic scores were developed based upon
these characteristics, such as the Pneumonia Patient
Outcomes Research Team score [6]. Ghanem-Zoubi et
al reported recently in a study that included 43% of
patients with pneumonia that simple clinical score and
mortality in emergency department sepsis scores were
the most appropriate clinical scores to predict the mor-
tality of patients with sepsis in general internal medicine
departments [7]. Although there is a large body of
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any medium, provided the original work is properly citedevidence in this field in the general population, less
focus was put in younger group of patients, even though
several recent studies showed that there is an increasing
number of hospital admissions due to CAP among
patients less than 60 years old [8]. Recently, it was
reported that procalcitonin is associated with the sever-
ity of illness in patients with severe pneumonia and
appears to be a prognostic marker of morbidity and
mortality [9].
Red Blood Cell Distribution Width (RDW) is a labora-
tory index used in the differential diagnosis of microcy-
tic anemia. Recently, several studies showed that a high
RDW index predicts severe morbidity and mortality in
various cardiac conditions, such as acute and chronic
congestive heart failure [10,11], pulmonary hypertension,
[12] and stroke. [13]
Therefore, our primary aim was to determine prog-
nostic factors that are associated with complicated hos-
pitalization and 90-day mortality. The major secondary
endpoint was to assess whether RDW is associated with
adverse outcome irrespective of hemoglobin and white
blood cell (WBC) levels.
Materials and methods
Patients 60 years old or younger, who were diagnosed
with CAP (defined as pneumonia identified 48 hours or
less from hospitalization) between 1 March, 2005 and
31 December, 2008 were retrospectively analyzed for
risk factors for severe morbidity or mortality. Data were
collected from the Prometheus, Rambam Integrated
Computer System for handling patients’ medical records,
and the 90-day mortality data were retrieved from the
database of our hospital and the ministry of health.
Complicated hospitalization was defined as at least
one of the following parameters: hospitalization longer
than 10 days, admission to ICU and in- hospital mortal-
ity. Otherwise, the hospitalization was defined as
uncomplicated. The Rambam Hospital Institutional
Review Board approved the study. The need for
informed consent was waived.
Exclusion criteria included transfer from another hos-
pital, hospitalization for any cause other than CAP dur-
ing the 30 days prior to admission, hospital-acquired
pneumonia (defined as pneumonia which was diagnosed
more than 48 hours after admission) or partial antibiotic
treatment before admission.
The following data were retrieved from the electronic
medical records of the patients:
(1) Malignancies: solid tumors, hematologic malignan-
cies. (2) Pulmonary diseases: bronchial asthma, chronic
obstructive lung disease, interstitial lung disease,
bronchiectasis, permanent tracheostomy, lung malig-
nancy, past history of thoracic radiotherapy, previous
episode of pneumonia, and previous or current active
smoker. (3) Immune suppression conditions: current
chronic corticosteroid treatment, current or recent che-
motherapy treatment, carrier of HIV, primary immune
deficiency, history of bone marrow transplantation. (4)
Cardiovascular diseases. (5) Chronic kidney disease. (6)
Diabetes mellitus. (7) Liver cirrhosis. (8) Prior neurolo-
gic damage. (9) Chronic alcohol use. (10) Intravenous
drug abuse. (11) Nursing house residents.
Laboratory variables on admission
Serum glucose, creatinine, sodium, hemoglobin, WBC,
RDW and blood urea nitrogen (BUN) were measured
on admission.
Hemoglobin levels, mean corpuscular volume and
RDW were measured on admission and prior to hospital
discharge, using the Advia 120 Hematology Analyzer
(Siemens Healthcare Diagnostics Deerfield, Illinois,
USA). Glucose, BUN and creatinine levels were mea-
sured using the “Dimension” (Siemens Healthcare Diag-
nostics Deerfield, Illinois, USA).
RDW is reported as coefficient of variation (in per-
cent) of red blood cell volume. The normal range for
RDW in our laboratory is 11.5 to 14.5%. The correct-
ness of this normal range was confirmed by analyzing
RDW data in 17,293 ambulatory subjects who attended
the Rambam Center for Preventive Medicine for a medi-
cal examination and health counseling. In this group,
mean RDW was 13.1% (median 13.0%) with 95% confi-
dence interval (CI) of RDW of 12.0 to 14.4%.
Statistical analysis
Binary logistic regression analysis was used for the calcula-
tion of the odds ratios (OR) with 95% CI and P values in
univariate analysis to identify association between patient
characteristic and 90-day mortality and complicated hospi-
talization. Multivariate forward stepwise logistic regression
was performed to assess the relation between patient char-
acteristics: co-morbidities, laboratory results, and 90-day
mortality or complicated hospitalizations.
Variables were selected as candidates for the multi-
variate analysis on the basis of the level of significance
of the univariate association with 90-day mortality and
complicated hospitalization (P < 0.1). Notably, there was
no predilection in choosing RDW or any other variable
in the statistical model.
The area under curve (AUC) was used as a measure of
model of discrimination. The calibration of the predic-
tion equation was assessed by comparing the observed
and expected numbers of 90-day mortality or compli-
cated hospitalization. The calibration of the prediction
equation was assessed by comparing the observed and
expected numbers of 90-day mortality or complicated
hospitalization rate by decile of predicted risk. The Hos-
mer-Lemeshow goodness-of-fit statistic was calculated.
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(complicated and uncomplicated) was done by using
chi-square test. Student’s t-test was used to compare age
between the two groups, whereas, length of stay was
compared using Mann-Whitney nonparametric test.
Two-tailed P values of 0.05 or less were considered as
statistically significant. All statistical analyses were per-
formed using SPSS (Statistics Products Solutions Ser-
vices; Armonk, New York, USA) 17.0 software for
Windows; Redmond, Washington, USA.
Results
The cohort included 637 patients; 63% were males,
median age was 46 years, the in-hospital mortality rate
was 6.6% and the median length of stay was five days.
Univariate analysis of complicated hospitalizations and
90-day mortality
As shown in Table 1, 171 patients (26%) experienced
complicated hospitalization; male patients and those
with co-morbid conditions tended to have a complicated
disease. Notably, patients who had concomitant diabetes
mellitus, chronic liver diseases, interstitial lung diseases
and past chemotherapy did not have a more compli-
cated course of CAP (P = not significant).
As depicted in Table 1, patients who had disturbed
renal function tests, anemia, abnormal WBC and ele-
vated RDW on admission had a complicated
hospitalization.
The median length of stay was 4 and 12 days in
uncomplicated and complicated patients, respectively. In
Table 1 Baseline characteristics of the cohort with univariate analysis of risk factors for detection of complicated
hospitalization
Characteristic NT (%) NUC (%) NC (%) Odds ratio (95% CI) P value
637 466 (73.2) 171 (26.8)
Gender Male 403 (63.3) 282 (60.5) 121 (70.8) 1.58 (1.082-2.305) 0.018
Female 234 (36.7) 184 (39.5) 50 (29.2) Reference 1.000
Age (years) ≤30 126 (19.8) 106 (27) 20 (11.7) Reference
31-40 136 (21.4) 97 (29.2) 39 (22.8) 2.13 (1.163-3.904) 0.014
41-50 144 (22.6) 109 (30.9) 35 (20.5) 1.70 (0.924-3.135) 0.088
51-60 231 (36.3) 154 (49.6) 77 (45.0) 2.65 (1.528-4.596) 0.001
Co-morbid conditions
Malignancy 60 (9.4%) 32 (6.9) 28 (16.4) 2.66 (1.546-4.563) <0.0001
Prior neurologic damage 125 (19.6%) 57 (12.2) 68 (39.8) 4.74 (3.134-7.160) <0.0001
Chronic renal failure 26 (4.1%) 15 (3.2) 11 (6.4) 2.07 (0.930-4.594) 0.075
Heart disease 56 (8.8%) 34 (7.3) 22 (12.9) 1.88 (1.063-3.310) 0.030
Lung disease* 193 (30.3%) 128 (27.5) 65 (38) 1.61 (1.115-2.337) 0.011
Asthma 41 (6.4%) 35 (7.5) 6 (3.5) 0.45 (0.185-1.084) 0.075
Chronic obstructive lung disease 77 (12.1%) 50 (10.7) 27 (15.8) 1.56 (0.941-2.585) 0.084
Lung malignancy 37 (5.8%) 20 (4.3) 17 (9.9) 2.46 (1.257-4.820) 0.009
Post chest radiation 31 (4.9%) 14 (3) 17 (9.9) 2.96 (1.074-8.146) 0.036
Immune deficiency 156 (24.5%) 98 )21) 58 (33.9) 1.93 (1.309-2.839) 0.001
Hematologic malignancy 45 (7.1%) 30 (6.4) 15 (8.8) 2.38 (0.944-5.982) 0.066
Corticosteroid therapy 76 (11.9%) 44 (9.4) 32 (18.7) 2.21 (1.347-3.619) 0.002
Nursing institution 52 (8.2%) 21 (4.5) 31 (18.1) 4.69 (2.612-8.427) <0.0001
SBP on admission (mmHg) 137.3 ± 32.1 137.9 ± 36.1 136.6 ± 29.0 1.009 (0.942-1.082) NS
DBP on admission (mmHg) 77.4 ± 16.1 77.8 ± 18.3 76.9 ± 12.6 1.011(0.945-1.081) NS
Heart rate on admission (min
-1) 86.7 ± 20.2 86.8 ± 20.6 86.7 ± 20.1 0.998 (0.926-1.077) NS
Laboratory parameters
BUN > 10.7 mmol/L 65 (10.2%) 35 (7.5) 30 (17.5) 2.62 (1.552-4.422) <0.0001
Creatinine >114 μmol/L 88 (13.8%) 54 (11.6) 34 (19.9) 1.89 (1.183-3.031) 0.008
Hemoglobin <110 g/L 113 (17.7%) 68 (14.6) 45 (26.3) 2.11 (1.375-3.229) 0.001
Hematocrit <30 mg/dl 56 (8.8%) 31 (6.7) 25 (14.6) 2.42 (1.383-4.233) 0.002
Glucose >13.8 mmol/L 39 (6.1%) 24 (5.2) 15 (8.8%) 1.77 (0.903-3.454) 0.096
WBC <4 or >12 × 10
9/L 347 (54.5%) 238 (51.1) 109 (63.7) 1.68 (1.174-2.416) 0.005
RDW >14.5% 218 (34.2%) 123 (26.4) 95 (55.6) 3.49 (2.419-5.023) <0.0001
P < 0.05 represents significant statistical difference between patients with complicated and uncomplicated hospitalization
BUN, blood urea nitrogen; CI, confidence interval; DBP, diastolic blood pressure; NC, number of complicated admissions; ns, not significant; NT, all the patients
that were included in the cohort; NUC, number of uncomplicated admissions as defined; RDW, red cell width distribution; SBP, systolic blood pressure; WBC, white
blood cells.
* Includes bronchial asthma, chronic obstructive lung disease, interstitial lung disease, bronchiectasis, permanent tracheostomy, lung malignancy, past history of
thoracic radiotherapy, previous episode of pneumonia, and previous or current active smoking.
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90-day mortality was 31% as compared with 3.9% in
uncomplicated patients (P < 0.03). Notably, the combina-
tion of elevated RDW and abnormal WBC count had the
highest OR for complicated hospitalization and 90-day
mortality (Tables 2 and 3 respectively). We found a sta-
tistically significant association between each element of
the complicated hospitalization and elevated RDW. For
length of stay of more than 10 days, linear regression
showed B = 3.5 (95% CI = 1.8-5.1, P < 0.0001). For ICU
admission logistic regression showed OR of 1.97 (95% CI
= 1.2-3.1, P = 0.004), and for in- hospital mortality, bin-
ary regression showed OR of 3.5 (95% CI = 2.4-5).
Multivariate analysis of complicated hospitalizations
All variables that were associated (P <0 . 1 )w i t hc o m p l i -
cated hospitalization were included in the initial multi-
variate prediction rule. Results of multivariate analysis
are presented in Table 4.
In a model that does not include RDW, variables that
were associated with complicated hospitalization
included prior neurologic damage, heard disease, prior
corticosteroid treatment; post chest radiation state, BUN
above 10.7 mmol/L and abnormal WBC.
Whenever RDW was included in the model, the vari-
ables that were associated with complicated hospitaliza-
tion included prior neurologic damage, post chest
radiation, BUN above 10.7 mmol/L and RDW above
14.5%. However, with the inclusion of both elevated
RDW and abnormal WBC, the variables that were
linked with complicated hospitalization included prior
neurologic damage; post chest radiation BUN above
10.7 mmol/L and combination of elevated RDW and
abnormal WBC. A model with RDW improved AUCROC
as compared with a model without RDW from 0.736
(95% CI = 0.691-0.781) to 0.743 (95% CI = 0.699-0.788);
conceivably, the improvement was prominent in a
model with the combination of RDW and abnormal
WBC from 0.736 to 0.755 (95% CI = 0.711-0.799). The
Hosmer-Lemeshev goodness-of-fit statistic across decile
of risk was not statistically significant indicating little
departure a perfect fit in all three models.
Multivariate analysis of 90-day mortality
All variables that were found to be associated (P<0.1)
with 90-day mortality in the univariate analysis (Table
5); were included in the initial multivariate prediction
rule. As depicted in Table 6; in the first model that
excluded RDW, variables that were associated with an
increased risk of 90-day mortality included age 51 years
or older, prior neurologic damage and immunosupres-
sion. Including RDW in the model demonstrated that
the same variables in addition to elevated RDW were
associated with increased 90-day mortality. Notably, the
model that joined both elevated RDW and abnormal
WBC; it was proved that this combination is signifi-
cantly associated with increased mortality in addition to
the three previous variables. The model with RDW
improved AUCROC as compared with a model without
RDW from 0.807 (95% CI = 0.746-0.868) to 0.822 (95%
CI = 0.766-0.879); while the model of combined elevated
RDW and abnormal WBC improved AUCROC from
0.807 to 0.828 (95% CI = 0.772-0.885). The Hosmer-
Lemeshev goodness-of-fit statistic across decile of risk
was not statistically significant, indicating little departure
from a perfect fit in all three models.
Table 2 The combination of elevated RDW and abnormal WBC count had the highest odds ratio for complicated
hospitalization
n (%) Complicated hospitalization (%) Odds ratio (95% CI) P value
637
RDW ≤14.5 4≤ WBC ≤12 × 10
9/L 197 (30.9) 15.7% Reference
WBC <4 or >12 × 10
9/L 222 (34.9) 20.3% 1.36 (0.82-2.25) 0.23
RDW >14. 4≤ WBC ≤12 × 10
9/L 93 (14.6) 33.3% 2.68 (1.5-4.77) 0.001
WBC <4 or >12 × 10
9/L 125 (19.6 51.2% 5.62 (3.34-9.45) <0.0001
CI, confidence interval; OR, odds ratio; RDW, red cell width distribution; WBC, white blood cells.
Table 3 The combination of elevated RDW and abnormal WBC count disclosed the highest OR for 90-day mortality
n (%) 90-day mortality (%) Odds ratio (95% CI) P value
637
RDW ≤14.5 4≤ WBC ≤12 × 10
9/L 197 (30.9) 2.0% Reference
WBC <4 or >12 × 10
9/L 222 (34.9) 5.0% 2.5 (0.8-8.0) 0.119
RDW >14. 4≤ WBC ≤12 × 10
9/L 93 (14.6) 8.6% 4.5 (1.3-15.5) 0.016
WBC <4 or >12 × 10
9/L 125 (19.6 15.2% 8.6 (2.9-26.1) <0.0001
CI, confidence interval; OR, odds ratio; RDW, red cell width distribution; WBC, white blood cells.
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Page 4 of 9Table 4 Results of multivariate analysis of risk factors for complicated hospitalization
Without RDW With RDW RDW and abnormal WBC
% from
Total
Coef. P
value
Adjusted odds
ratio
95%
confidence
interval
Coef. P
value
Adjusted odds
ratio
95%
confidence
interval
Coef. P
value
Adjusted odds
ratio
95%
confidence
interval
Lower Upper Lower Upper Lower Upper
Prior neurologic damage 19.6 1.7 <0.0001 5.3 3.4 8.2 1.5 <0.0001 4.5 2.9 7.0 1.6 <0.0001 4.7 3.0 7.3
Heart disease 8.8 0.6 0.044 1.9 1.0 3.5
Corticosteroid therapy 11.9 0.7 0.01 2 1.2 3.5
Post chest radiation 4.9 1.4 <0.001 4.1 1.9 8.9 1.1 0.006 3.1 1.4 6.9 1.1 0.007 3.0 1.4 6.8
BUN >10.7 mmol/L 10.2 0.8 0.008 2.2 1.2 3.8 0.8 0.004 2.3 1.3 4.1 0.8 0.004 2.3 1.3 4.1
WBC <4 or >12 × 10
9/L 54.5 0.6 0.004 1.8 1.2 2.7
RDW ≤14.5% 34.2 1.0 <0.0001 2.9 1.9 4.2
RDW ≤14.5% and WBC =
normal
31 <0.0001 Reference
RDW >14.5% and WBC =
normal
49 0.5 0.048 1.7 1.0 3.0
RDW >14.5% and WBC =
abnormal
20 1.4 <0.0001 4.1 2.6 6.5
Constant -2.084 -1.96 -1.97
Hosmer and Lemeshow
Test
0.543 0.344 0.565
Area under curve 0.7376 0.691 0.781 0.743 0.699 0.788 0.755 0.711 0.799
Elevated RDW levels on admission either alone or in combination of abnormal levels of white blood are associated with significant higher rates complicated hospitalization.
BUN, blood urea nitrogen; Coef, coefficient; RDW, red cell width distribution; WBC, white blood cells.
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9The association of RDW and complicated hospitalization
Ninety five (55.6%) patients with complicated hospitali-
zation had increased RDW as compared with 123 (26%)
patients with uncomplicated admissions (P<0.0001).
Complicated hospitalization and mortality rates were
significantly higher among patients with increased RDW
regardless of the WBC count (Figure 1); the complicated
hospitalization rate was 15.7% in patients with normal
RDW and WBC and 20.3% in patients with only abnor-
mal WBC count, as compared with 33.3% in patients
with elevated RDW alone (P = 0.001) and 51.2% in
patients with combined abnormal leukocyte count and
increased RDW (P<0.001). As shown in Figure 1, the 90-
day mortality was higher in patients with elevated RDW
regardless of the WBC count; however, once again the
combination of abnormal WBC and elevated RDW was
significantly associated with the highest mortality rates.
In order to rule out the possibility that RDW effect on
severe morbidity and mortality was unrelated to anemia,
we compared complicated hospitalization in patients
with hemoglobin (Hb) levels less than 110 g/L and
higher levels of Hb. The two groups were examined in
patients with normal and elevated RDW. As depicted in
Figure 2, patients with normal RDW had no difference
in severe morbidity or mortality regardless of Hb levels.
On the other hand, elevated RDW was associated with a
significant increase in both complicated hospitalization
and 90-day mortality rates irrespective of Hb levels.
Discussion
This study shows that in young patients with CAP, ele-
vated RDW levels on admission either alone or in
combination with abnormal levels of WBC are asso-
ciated with significant higher rates of mortality and
complicated hospitalization. RDW level as a prognostic
marker was unrelated to hemoglobin levels on
admission.
RDW is a simple laboratory test used to evaluate var-
iance in the size and form of red blood cells. It is an
important marker in the differential diagnosis of anemia.
However, RDW was shown to be a predictor of severe
morbidity and mortality in several cardiac problems
[10-12,14]. There is a large body of evidence showing
that RDW is a strong predictor for an adverse outcome
in these conditions, equivalent to other known markers,
such as low ejection fraction, high New York Heart
Association Functional Classification (NYHA) score and
elevated serum B-Type Natriuretic peptide (BNP) levels
[15]. Moreover, it was recently reported that RDW is a
strong predictor of mortality in several other conditions
such as obesity, malignancies, and chronic kidney dis-
ease [16]. Concordant with our findings, Wang et al.
reported recently that a graded independent relation
between higher RDW and adverse outcomes in ICU
patients [17].
Several explanations were suggested to this surprising
finding. Abnormal RDW usually suggests one or more
chronic condition that accompanies significant heart
failure, such as anemia or nutritional deficit. Another
mechanism that was suggested is the release of cyto-
kines in response to inflammatory stress. These cyto-
kines block the activity of erythropoietin and cause
production of ineffective red blood cell and elevated
RDW [18,19]. Lippi et al found a correlation between
Table 5 Univariate analysis of risk factors for detection of 90-day mortality
Characteristic NT 90-day mortality n (%) Odds ratio (95% CI) P value
637
Gender Male 403 28 (6.9) 1.17 (0.605-2.276) 0.64
Female 234 14 (6.0) Reference 1.000
Age groups (years) ≤30 126 5 (4.0) Reference
31-40 136 4 (2.9) 0.73 (0.192-2.794) 0.65
41-50 144 6 (4.2) 1.05 (0.313-3.543) 0.93
51-60 231 27 (11.7) 3.2 (1.202-8.537) 0.02
Malignancy 60 11 (18.3) 3.95 (1.873-8.349) <0.0001
Prior neurologic damage 125 22 (17.6) 5.25 (2.766-9.982) <0.0001
Post chest radiation 31 17 (9.9) 3.56 (1.716-7.400) 0.001
Immune deficiency 156 19 (12.2%) 2.76 (1.461-5.221) 0.002
Corticosteroid therapy 76 10 (13.2%) 2.50 (1.178-5.328) 0.017
Nursing institution 52 10 (19.2%) 4.11 (1.893-8.942) <0.0001
BUN >10.7 mmol/L 65 9 (13.8%) 2.62 (1.195-5.765) 0.016
Hemoglobin <110 g/L 113 12 (10.6%) 2.02 (0.999-4.100) 0.050
WBC <4 or >12 × 10
9/L 347 30 (8.6%) 2.19 (1.101-4.365) 0.025
RDW >14.5% 218 27 (12.4%) 3.81 (1.979-7.324) <0.0001
BUN, blood urea nitrogen; CI, confidence interval; NT, all the patients that were included in the cohort; RDW, red cell width distribution; WBC, white blood cells.
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Page 6 of 9Table 6 Results of multivariate analysis of risk factors for 90-day mortality
Without RDW With RDW RDW and abnormal WBC
% from
total
Coef. P
value
Adjusted odds
ratio
95%
confidence
interval
Coef. P
value
Adjusted odds
ratio
95%
confidence
interval
Coef. P
value
Adjusted odds
ratio
95%
confidence
interval
Lower Upper Lower Upper Lower Upper
Age ≥51 years 36.3 1.2 0.001 3.3 1.7 6.5 1.1 0.001 3.1 1.6 6.2 1.0 0.003 2.8 1.4 5.6
Prior neurologic damage 19.6 1.7 <0.0001 5.3 2.7 10.2 1.6 <0.0001 4.9 2.5 9.7 1.6 <0.0001 5.0 2.6 10.0
Immunedeficiency 24.5 1.1 0.001 3.1 1.6 6.2 0.8 0.001 3.1 1.6 6.2 0.9 0.012 2.5 1.2 5.0
RDW ≤14.5% 34.2 0.8
RDW ≤14.5% and WBC =
normal
30.9 0.016 Reference
RDW >14.5% or WBC =
normal
49.5 0.9 0.128 2.4 0.8 7.3
RDW >14.5% and WBC =
abnormal
19.6 1.6 0.007 4.8 1.5 15.3
Constant -4.187 -4.453 -4.937
Hosmer and Lemeshow
Test
0.310 0.363 0.708
Area under curve 0.807 0.746 0868 0.822 0.766 0879 0.828 0.772 0885
Elevated RDW either alone or in combination with abnormal WBC, proved to be significantly associated with increased mortality.
Coef, coefficient; RDW, red cell width distribution; WBC, white blood cells.
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9high RDW and elevated indexes of inflammation, such
as elevated erythrocyte sedimentation rate (ESR) and C-
reactive protein (CRP). This correlation was indepen-
dent of concomitant diseases, and was demonstrated
even when anemic patients were excluded from the sta-
tistical analysis [20].
Our data demonstrated that RDW is a valuable and
sensitive marker for a high level of inflammatory activity
in young patients with CAP, and it is independent of
hemoglobin levels. The mechanism underlying the asso-
ciation between high levels of RDW and adverse out-
come in patients hospitalized with pneumonia is
unknown. RDW is elevated in conditions in which there
is ineffective red cell production or increased destruc-
tion of red blood cell. RDW may indicate a severe
inflammatory process, with impact on bone marrow
function and iron metabolism. Another option is that
RDW is an earlier marker of prognosis, and it may
appear earlier in the complex process of anemia than
low levels of hemoglobin. As noted before, high RDW
levels may represent a culmination of multiple patho-
physiologic processes occurring in acute inflammatory
and infectious state.
Measuring RDW on admission is relatively simple and
can be done during routine evaluation at the emergency
r o o m .O u rd a t as u g g e s tt h a ti tm a yo f f e rt h ep h y s i c i a n
another tool in the process of decision making whether
to admit a patient diagnosed with CAP, in addition to
the various scores that were developed in recent years
for this purpose. Indeed, if RDW is proven to be a prog-
nostic factor in older patients admitted with CAP, it
might even be incorporated into such scores. In concor-
dance with our data, several studies demonstrated the
relation between mortality and elevated RDW in middle
aged and older adults [21,22]. To our knowledge, our
study is the first to show the poor prognostic effect of
elevated RDW in young patients with CAP.
The major limitation of this study is its retrospective
nature. In addition, our study examined RDW as a prog-
nostic factor only in patients 60 years old and less. The
majority of mortality and severe mortality in patients
with CAP is in elderly patients, many of them have
chronic hematologic and inflammatory co-morbidities.
A larger cohort of this complex population is needed to
clarify RDW as an independent risk factor in this popu-
lation and to validate it prospectively including other
inflammatory markers such as CRP, procalcitonin and
IL-6. Notably, our study was planned to detect the asso-
ciation between elevated RDW and prognosis of CAP;
however, we did not examine whether this observation
is unique to CAP or could be demonstrated in other
inflammatory and infectious states.
Conclusions
In young patients with CAP, elevated RDW levels are
associated with significant higher rates of mortality and
severe morbidity. RDW as a prognostic marker was
unrelated with hemoglobin levels on admission.
Key messages
￿ Elevated RDW on admission is a recently described
risk factor for adverse outcome in cardiac problems.
￿ This study demonstrates that elevated RDW in
young patients hospitalized with CAP is a significant
risk factor for complicated hospitalization and in-
hospital mortality.
￿ Conceivably, measuring RDW in the emergency
department might offer the clinician a simple yet
powerful tool in the process of decision making
whether to admit patients with CAP.
Abbreviations
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